의약품부작용보고원시자료 기반 약물 아나필락시스 사례 분석
Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose: To identify causative agents of the drug-induced anaphylaxis (DIA) by using the KIDS-KAERS (Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System) database (Ministry of Food and Drug Safety) in Korea and to check their labeling information regarding anaphylaxis. Methods: Among Individual Case Safety Reports from January, 2008 to December 2017, cases of DIA were analyzed for demographics, causative agents and fatal cases resulting in death. The domestic drug labeling, Micromedex and U.S. Food and Drug Administration (FDA) drug package insert, were reviewed to check if the labeling information on suspected causative agents contains anaphylaxis. Results: A total of 4,700 cases of DIA were analyzed. The mean age was 49.85±18.32 years, and 2,642 patients (56.2%) were females. Among 8,664 drugs reported as causative agents, antibiotics (27.4%) accounted for the largest portion. There were 18 fatal cases: antibiotics (7 cases), antineoplastic agents (4 cases) were the major causative drugs for the mortality cases. Of 513 drugs reported as suspected causative agents, 103 (20.1%) did not list anaphylaxis as an adverse effect on domestic drug labeling and 16 (3.1%) did not reflect anaphylaxis in any of 3 adverse drug information. Conclusion: Analysis of 10-year data showed that antibiotics were the main cause of DIA and the mortality rate was 0.7%. In 3.1% of suspected drugs, there was no description of anaphylaxis in any of the drug labeling.
Abstract
Purpose: To identify causative agents of the drug-induced anaphylaxis (DIA) by using the KIDS-KAERS (Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System) database (Ministry of Food and Drug Safety) in Korea and to check their labeling information regarding anaphylaxis. Methods: Among Individual Case Safety Reports from January, 2008 to December 2017, cases of DIA were analyzed for demographics, causative agents and fatal cases resulting in death. The domestic drug labeling, Micromedex and U.S. Food and Drug Administration (FDA) drug package insert, were reviewed to check if the labeling information on suspected causative agents contains anaphylaxis. Results: A total of 4,700 cases of DIA were analyzed. The mean age was 49.85±18.32 years, and 2,642 patients (56.2%) were females. Among 8,664 drugs reported as causative agents, antibiotics (27.4%) accounted for the largest portion. There were 18 fatal cases: antibiotics (7 cases), antineoplastic agents (4 cases) were the major causative drugs for the mortality cases. Of 513 drugs reported as suspected causative agents, 103 (20.1%) did not list anaphylaxis as an adverse effect on domestic drug labeling and 16 (3.1%) did not reflect anaphylaxis in any of 3 adverse drug information. Conclusion: Analysis of 10-year data showed that antibiotics were the main cause of DIA and the mortality rate was 0.7%. In 3.1% of suspected drugs, there was no description of anaphylaxis in any of the drug labeling.
참고문헌 (17)
- Bochner BS, "Anaphylaxis", N Engl J Med, 324, pp.1785~1790 (1991)
- Wood RA, "Anaphylaxis in America : the prevalence and characteristics of anaphylaxis in the United States", J Allergy Clin Immunol, 133, pp.461~467 (2014)
- Jeong K, "A population-based epidemiological study of anaphylaxis using national big data in Korea : trends in age-specific prevalence and epinephrine use in 2010-2014", Allergy Asthma Clin Immunol, 14, pp.31~ (2018)
- Zhao Y, "Drug-induced anaphylaxis in China : a 10 year retrospective analysis of the Beijing Pharmacovigilance Database", Int J Clin Pharm, 40, pp.1349~1358 (2018)
- 예영민, "Predictors of the Severity and Serious Outcomes of Anaphylaxis in Korean Adults: A Multicenter Retrospective Case Study", Allergy, Asthma & Immunology Research, 7(1), pp.22~29 (2015), 대한천식알레르기학회
- Jerschow E, "Fatal anaphylaxis in the United States, 1999-2010 : temporal patterns and demographic associations", J Allergy Clin Immunol, 134, pp.1318~1328.e7 (2014)
- Yang MS, "Epidemiologic and clinical features of anaphylaxis in Korea", Ann Allergy Asthma Immunol, 100, pp.31~36 (2008)
- 문일주, "단일 3차 의료 기관의 약물 유발 아나필락시스 발생 현황", 대한내과학회지, 88(3), pp.281~287 (2015), 대한내과학회[DOI]
- Carneiro-Leão L, "Pemetrexed anaphylaxis-an unusual suspect", J Allergy Clin Immunol Pract, 7, pp.320~321 (2019)
- 유혜수, "A Case of Codeine Induced Anaphylaxis via Oral Route", Allergy, Asthma & Immunology Research, 6(1), pp.95~97 (2014), 대한천식알레르기학회
- Donado CD, "Successful desensitization for hydroxychloroquine anaphylaxis", J Rheumatol, 37, pp.1975~1976 (2010)
- Faria E, "Drug-induced anaphylaxis survey in Portuguese Allergy Departments", J Investig Allergol Clin Immunol, 24, pp.40~48 (2014)
- 2018 Drug safety information report, "Korea Institute of Drug Safety & Risk Management", Korea Institute of Drug Safety & Risk Management, ~ (2018)
- 구자현, "Ranitidine 정주 후 발생한 아나필락시스 2예-증례 보고-", Acute and Critical Care, 25(4), pp.253~256 (2010), 대한중환자의학회
- Chopra D, "Anaphylaxis following intravenous ranitidine : a rare adverse reaction of a common drug", Indian J Pharmacol, 46, pp.234~236 (2014)
- Park KH, "Ranitidine-induced anaphylaxis : clinical features, cross-reactivity, and skin testing", Clin Exp Allergy, 46, pp.631~639 (2016)
- Kim H, "Anaphylaxis", Allergy Asthma Clin Immunol, 7(Suppl 1), pp.S6~ (2011)